Tony Su retweeted
Please join us in congratulating Dr. Amin Herati and Dr. Sunil Patel on their promotions to Associate Professor!
These well-earned promotions reflect their dedication to exceptional patient care, investment in educating the next generation of physicians, and meaningful research.
These well-earned promotions reflect their dedication to exceptional patient care, investment in educating the next generation of physicians, and meaningful research.
0
5
28
1,313
Tony Su retweeted
With VOLGA results coming at #ESMO26, a summary of contemporary phase III perioperative trials in muscle-invasive bladder cancer.
⚠️ Different populations and designs—avoid cross-trial comparisons. VOLGA and EV-303 importantly include surgery-alone control arms without The next challenge: identifying who truly needs adjuvant ADC therapy—and who can safely avoid it.
#BladderCancer #GUOnc @OncoAlert @BladderCancerUS
⚠️ Different populations and designs—avoid cross-trial comparisons. VOLGA and EV-303 importantly include surgery-alone control arms without The next challenge: identifying who truly needs adjuvant ADC therapy—and who can safely avoid it.
#BladderCancer #GUOnc @OncoAlert @BladderCancerUS
4
61
118
10,588
Tony Su retweeted
Congratulations to the Brady Urological Institute physicians recognized by their peers as 2026 Baltimore Magazine Top Doctors!
We’re proud to celebrate their expertise and commitment to exceptional care for patients across the Baltimore area.
We’re proud to celebrate their expertise and commitment to exceptional care for patients across the Baltimore area.
1
3
18
1,208
Tony Su retweeted
PROTEUS Substudy: Periop Apa + ADT with RP+PLND vs RP+PLND in HR PCa @urotoday #ESMO26
Periop APA + ADT (+ RP+PLND; n= 102) vs RP+PLND alone (n=306)
🚨EFS: HR 0.38, 95% CI 0.26–0.55
🚨MFS: HR 0.49, 95% CI 0.26–0.90
🚨TT 1st Sub Rx: HR 0.29, 95% CI 0.20–0.43
🚨All Gr Hot Flush: 64% vs 0.7%
Periop APA + ADT (+ RP+PLND; n= 102) vs RP+PLND alone (n=306)
🚨EFS: HR 0.38, 95% CI 0.26–0.55
🚨MFS: HR 0.49, 95% CI 0.26–0.90
🚨TT 1st Sub Rx: HR 0.29, 95% CI 0.20–0.43
🚨All Gr Hot Flush: 64% vs 0.7%
4
56
124
16,838
Tony Su retweeted
A landmark trial found that a combination treatment for people with bladder cancer significantly improved outcomes after 2 years. Researchers found this approach is also likely cost-effective: tinyurl.com/y7fmdm8u @JAMANetworkOpen @brady_urology
1
3
6
492
Thx to @JAMANetworkOpen for publishing our cost-effectiveness study of periop EV-pembro for cisplatin-ineligible MIBC
@MaxKates @SBoorjian @tbivala1 @m_e_nielsen @siadaneshmand @SHPatelMD1 @nirmishsingla @JCensits @akfsurgeon @Sood11 @HitenDPatel @RuchikaTalwarMD @brady_urology
@MaxKates @SBoorjian @tbivala1 @m_e_nielsen @siadaneshmand @SHPatelMD1 @nirmishsingla @JCensits @akfsurgeon @Sood11 @HitenDPatel @RuchikaTalwarMD @brady_urology
For cisplatin-ineligible muscle-invasive #BladderCancer, perioperative #EnfortumabVedotin plus pembrolizumab with radical cystectomy was associated with improved survival and was cost-effective vs radical cystectomy alone over 10 years. ja.ma/4seltqJ
3
7
24
3,265
I/O therapies associated w/ many of the highest total industry-sponsored research payments to US physician PIs during 2016-2022
@PLOSONE
journals.plos.org/plosone/articl…
@misophan
@brucetrock
@LoganGalanskyMD
@brady_urology
@PLOSONE
journals.plos.org/plosone/articl…
@misophan
@brucetrock
@LoganGalanskyMD
@brady_urology
1
0
4
136
Tony Su retweeted
🚽 Is Gem/Doce the Future for Bladder Cancer Treatment?
Gem/Doce shows promise as a first-line treatment for BCG-naïve high-risk NMIBC, offering new hope during BCG shortages.
📈 Efficacy - 3-year high-grade recurrence-free survival is 80%
🔬 Tolerability - Only 8% stopped due Future Potential - Phase 3 trials needed for standard care status
#BladderCancer #GemDoce #ClinicalTrials
tnyp.me/xRumFw21/x
Gem/Doce shows promise as a first-line treatment for BCG-naïve high-risk NMIBC, offering new hope during BCG shortages.
📈 Efficacy - 3-year high-grade recurrence-free survival is 80%
🔬 Tolerability - Only 8% stopped due Future Potential - Phase 3 trials needed for standard care status
#BladderCancer #GemDoce #ClinicalTrials
tnyp.me/xRumFw21/x
3
30
57
11,420
Tony Su retweeted
New paper out in @EurUrolOncol! 🧬
We present the largest prospective cohort of sporadic bilateral/multifocal papillary RCC (89 patients, 25 years at the NCI).
Key findings:
📉 Slow, indolent growth (median 1.55 mm/yr)
🎯 No metastases when largest tumor <3cm
🔬 Low metastatic rate overall (6.7%)
🩺 Repeat ipsilateral partial nephrectomy = biggest hit to kidney function
Supports active surveillance for small renal masses + nephron-sparing surgery when intervention is needed.
@markballmd
@RubenBlachmanMD
@MillanBraden
@patmichael93
Natural History, Tumor Growth Kinetics, and Renal Functional Outcomes... sciencedirect.com/science/articl…
We present the largest prospective cohort of sporadic bilateral/multifocal papillary RCC (89 patients, 25 years at the NCI).
Key findings:
📉 Slow, indolent growth (median 1.55 mm/yr)
🎯 No metastases when largest tumor <3cm
🔬 Low metastatic rate overall (6.7%)
🩺 Repeat ipsilateral partial nephrectomy = biggest hit to kidney function
Supports active surveillance for small renal masses + nephron-sparing surgery when intervention is needed.
@markballmd
@RubenBlachmanMD
@MillanBraden
@patmichael93
Natural History, Tumor Growth Kinetics, and Renal Functional Outcomes... sciencedirect.com/science/articl…
2
23
49
4,082
Tony Su retweeted
As our chief residents and fellows graduate, we recognize the outstanding educators and mentors who shaped their training. Congratulations to our 2026 Teaching Award recipients:
Resident Teaching Award: Naren Nimmagadda, M.D.
Allied Health Care Award: Kalli Veldman, MSN, RN
Resident Teaching Award: Naren Nimmagadda, M.D.
Allied Health Care Award: Kalli Veldman, MSN, RN
1
3
13
2,736
Incredibly bittersweet to leave Hopkins after 10 years. Thank you @brady_urology mentors, colleagues and friends for all your guidance, generosity, support, and encouragement over the last 6 years. Excited for the chapter ahead!
Brady Graduation 2026 - Sending off Tony, Logan, and Lamont into the next chapter of their careers. What a privilege to have been part of your journey! We are so proud of you and wish you all the success and happiness in the years ahead. @LoganGalanskyMD @ztonysu @allaf_mo
0
1
14
2,051
Tony Su retweeted
Incredible Commitment to Cancer Research by @davidjtrone. Trone Family Division of Urologic Oncology will be a place to accelerate innovation and progress for cancer patients everywhere. giving.jhu.edu/story/brady-ur…. @brady_urology
🎉 Big news at @brady_urology! Deeply grateful for a transformational gift to establish the Trone Family Division of Urologic Oncology under leadership of @MaxKates! Honored & Inspired by @davidjtrone to "move the needle towards better cancer outcomes" giving.jhu.edu/story/brady-ur…
1
4
37
3,448
Thankful for #AUA best poster award for our study showing periop durvalumab + neoadjuvant gem/cis is cost-effective for cisplatin-eligible MIBC, now published in @JNCCN
@MaxKates @SHPatelMD1 @JeffTownsend @JCensits @IFlorissi @AnneEGeller @brady_urology
jnccn.org/view/journals/…
@MaxKates @SHPatelMD1 @JeffTownsend @JCensits @IFlorissi @AnneEGeller @brady_urology
jnccn.org/view/journals/…
0
1
11
850
Thankful for @AmerUrological highlighting our work on links between diet patterns and prostate cancer grade progression in active surveillance
@brady_urology Christian Pavlovich @brucetrock Jack Campbell @HopkinsMedNews
@brady_urology Christian Pavlovich @brucetrock Jack Campbell @HopkinsMedNews
Don't miss the Press Program abstract, "Adherence to the Mediterranean and plant-based diets is associated with reduced risk of prostate cancer grade progression on active surveillance," being presented in the 9:30 a.m. session in 145AB.
Read here ➡️ bit.ly/4tMVmr1
#AUA26
0
1
2
592
Tony Su retweeted
The #EMBRACETrial: An enhanced recovery after surgery pathway for transurethral resection of bladder tumors. @mihiggins22 & @MaxKates @brady_urology join @UroCancerMD to discuss an enhanced recovery protocol for ambulatory TURBT which improved Quality of Recovery-15 scores by 12 poinnt clinical significance threshold—and reduced urethral pain, dysuria, incontinence, and 30-day outpatient visits. #WatchNow to learn more > bit.ly/3NqT3tH
1
9
19
2,718
Our @JNCCN study showed peri-op durvalumab w/ neoadjuvant gem/cis is cost-effective vs cisplatin-based NAC w/ risk-adapted adjuvant therapy for cisplatin-eligible MIBC treatment
@MaxKates @SHPatelMD1 @JCensits @JeffTownsend Noah Hahn @brady_urology
doi.org/10.6004/jnccn.…
@MaxKates @SHPatelMD1 @JCensits @JeffTownsend Noah Hahn @brady_urology
doi.org/10.6004/jnccn.…
0
3
5
837
Prospective data from @brady_urology PCa AS program showed increased physical activity levels, compared to a sedentary lifestyle defined as <3 MET-h/wk, is associated w/ lower risk of progression to ≥GG3 disease on AS @pcan_journal
@mihiggins22 Christian Pavlovich @brucetrock
@mihiggins22 Christian Pavlovich @brucetrock
2
1
10
808